Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse…
FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of…
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Phase III trial informed by comprehensive KARDIA data set generated through three…
Ram Rattan Group Launches The Green Step Farms Phase 2 & Aravalli Retreat in Ram Rattan’s Naugaon
NEW DELHI, Aug. 23, 2025 /PRNewswire/ -- Ram Rattan Group has launched…
Hexaware and upGrad Launch Agentic AI Academy to Power Phase 2 of AI Workforce Transformation
A Deep-skilling Initiative to Advance Hexaware's Agentic AI Capabilities MUMBAI, India and LONDON…
First Phase of IIPD Kasaragod, a Model Project to Empower Individuals with Disabilities, to be Completed in 2026, Fully Operational by 2029
THIRUVANANTHAPURAM, India, Aug. 18, 2025 /PRNewswire/ -- The first phase of the…
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001
CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Jabez Biosciences, Inc.,…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in…
